Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer

被引：43
|
作者：
Papadopoulou, E
Davilas, E
Sotiriou, V
Koliopanos, A
Aggelakis, F
Dardoufas, K
Agnanti, NJ
Karydas, L
Nasioulas, G
机构：
[1] HYGEIA Antonios Papayannis, Mol Biol Res Ctr, Athens 15123, Hellas, Greece
[2] HYGEIA, Duagnost & Therapeut Ctr Athens, Urol Clin, Athens 15123, Hellas, Greece
[3] Gen State Hosp Athens G Gennimatas, Surg Clin, Athens, Hellas, Greece
[4] HYGEIA, Ctr Radiat Oncol, Diagnost & Therapeut Ctr Athens, Athens 15123, Hellas, Greece
[5] Univ Ioannina, Sch Med, Dept Pathol, Hellas, Greece
[6] HYGEIA, Breast Ctr, Diagnost & Therapeut Ctr Athens, Athens 15123, Greece
来源：
ONCOLOGY RESEARCH | 2004年 / 14卷 / 09期
关键词：
prostate-specific membrane antigen (PSMA); glutathione-S-transferase P1 (GSTP1); carcinoembryonic antigen (CEA); DNA quantification;
D O I：
10.3727/0965040041791473
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Extracellular nucleic acids could serve as molecular markers in the early detection of cancer and in the prediction of disease outcome. In this study we examined six molecular markers, such as: variations in the quantity of DNA in plasma, glutathione-S-transferase P1 (GSTP1) gene methylation status in plasma, carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) mRNA in peripheral blood mononuclear cells (PBMC), and plasma samples from prostate cancer patients in different stages. The combination of DNA load and GSTP1 promoter methylation status identified 83% (10/12) of the prostate cancer patients before therapy. This study shows that free circulating DNA can be detected in patients with prostate cancer compared with disease-free individuals, and suggests a new, noninvasive approach for early detection of prostate cancer.
引用
收藏
页码：439 / 445
页数：7
相关论文
共 50 条
  • [21] Molecular phenotype classification of metastatic prostate cancer by cell-free DNA methylation analysis
    Adil, Mohamed
    Hanratty, Brian
    Mustafi, Pallabi
    Coleman, Ilsa
    Patel, Radhika
    Doebley, Anna-Lisa
    Patton, Robert
    Cruikshank, Eden
    Galipeau, Patricia
    Dumpit, Ruth
    Roudier, Martine
    Low, Jin-Yih
    De Sarkar, Navonil
    Montgomery, Robert
    Corey, Eva
    Morrissey, Colm
    Nelson, Peter
    Ha, Gavin
    Haffner, Michael
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Cell-free DNA as a diagnostic marker for cancer: current insights
    Salvi, Samanta
    Gurioli, Giorgia
    De Giorgi, Ugo
    Conteduca, Vincenza
    Tedaldi, Gianluca
    Calistri, Daniele
    Casadio, Valentina
    ONCOTARGETS AND THERAPY, 2016, 9 : 6549 - 6559
  • [23] Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer
    Fernandez-Garcia, Daniel
    Hills, Allison
    Page, Karen
    Hastings, Robert K.
    Toghill, Bradley
    Goddard, Kate S.
    Ion, Charlotte
    Ogle, Olivia
    Boydell, Anna Rita
    Gleason, Kelly
    Rutherford, Mark
    Lim, Adrian
    Guttery, David S.
    Coombes, R. Charles
    Shaw, Jacqueline A.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [24] Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer
    Daniel Fernandez-Garcia
    Allison Hills
    Karen Page
    Robert K. Hastings
    Bradley Toghill
    Kate S. Goddard
    Charlotte Ion
    Olivia Ogle
    Anna Rita Boydell
    Kelly Gleason
    Mark Rutherford
    Adrian Lim
    David S. Guttery
    R. Charles Coombes
    Jacqueline A. Shaw
    Breast Cancer Research, 21
  • [25] Total cell-free DNA level in plasma as strong prognostic marker in metastatic colorectal cancer
    Spindler, K. -L.
    Demuth, C.
    Soerensen, B.
    Johansen, J.
    Nielsen, D.
    Pallisgaard, N.
    Hogdall, E.
    Pfeiffer, P.
    Yilmaz, M.
    Jensen, B.
    ANNALS OF ONCOLOGY, 2016, 27 : 102 - 102
  • [26] The emerging role of cell-free DNA as a molecular marker for duodenal adenocarcinoma
    Lai, Hon-Fan
    Wang, Shin-E
    Chen, Shih-Chin
    Shyr, Bor-Shiuan
    Shyr, Yi-Ming
    Shyr, Bor-Uei
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2024, 87 (04) : 422 - 427
  • [27] A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer
    Peter, Madonna R.
    Bilenky, Misha
    Shi, Yuliang
    Pu, Jiajie
    Kamdar, Shivani
    Hansen, Aaron R.
    Fleshner, Neil E.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    Hirst, Martin
    Xu, Wei
    Bapat, Bharati
    EPIGENOMICS, 2022, 14 (13) : 811 - 822
  • [28] Tumor fraction in cell-free DNA as a biomarker in prostate cancer
    Choudhury, Atish D.
    Werner, Lillian
    Francini, Edoardo
    Wei, Xiao X.
    Ha, Gavin
    Freeman, Samuel S.
    Rhoades, Justin
    Reed, Sarah C.
    Gydush, Gregory
    Rotem, Denisse
    Lo, Christopher
    Taplin, Mary-Ellen
    Harshman, Lauren C.
    Zhang, Zhenwei
    O'Connor, Edward P.
    Stover, Daniel G.
    Parsons, Heather A.
    Getz, Gad
    Meyerson, Matthew
    Love, J. Christopher
    Hahn, William C.
    Adalsteinsson, Viktor A.
    JCI INSIGHT, 2018, 3 (21):
  • [29] Cell-free plasma DNA for the diagnosis and follow-up of prostate cancer patients.
    Wroclawski, Marcelo L.
    Serpa, Ary
    Fonseca, Fernando L. A.
    Neves Neto, Oseas Castro
    Pompeo, Antonio C. L.
    Machado, Marcos Tobias
    Del Giglio, Auro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Prostate cancer (PCA) patients display significant higher plasma levels of cell-free DNA
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 185 - 185
12345